Hemophagocytic lymphohistiocytosis after chemotherapy for multiple myeloma

Clin Lymphoma. 2004 Dec;5(3):194-6. doi: 10.3816/clm.2004.n.026.

Abstract

Secondary hemophagocytic lymphohistiocytosis has been reported after infections in immunocompromised hosts or in association with several malignancies. We report a case of secondary hemophagocytic syndrome after chemotherapy for multiple myeloma, which responded dramatically to dexamethasone, etoposide, and cyclosporin A.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biopsy, Needle
  • Bone Marrow / pathology
  • Cyclosporine / administration & dosage
  • Dexamethasone / administration & dosage
  • Etoposide / administration & dosage
  • Histiocytosis, Non-Langerhans-Cell / chemically induced*
  • Histiocytosis, Non-Langerhans-Cell / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Treatment Outcome

Substances

  • Etoposide
  • Dexamethasone
  • Cyclosporine